Phospho-PKMYT1 (Ser83) Antibody

What is PKMYT1 and what is its canonical function in cell cycle regulation?

PKMYT1 (Protein Kinase Membrane Associated Tyrosine/Threonine 1, also known as Myt1) is a serine/threonine kinase that plays a critical role in cell cycle regulation. Its canonical function involves inhibiting CDK1 activity by phosphorylating CDK1 at Tyr15 and Thr14 residues, which prevents CDK1's association with cyclin B. While WEE1 kinase can also phosphorylate CDK1 at Tyr15, PKMYT1 is uniquely responsible for phosphorylating CDK1 at the Thr14 residue. This phosphorylation mechanism serves as a crucial checkpoint preventing premature entry into mitosis until the cell is properly prepared for division. PKMYT1 essentially functions as a negative regulator of the G2/M transition, ensuring genomic integrity during cell division.

Recent research has demonstrated that PKMYT1 may have additional functions beyond CDK1 regulation, particularly in cancer cells where it appears to regulate PLK1 expression and phosphorylation, contributing to its oncogenic properties .

How should Phospho-PKMYT1 (Ser83) Antibody be used in Western blotting applications?

For optimal Western blotting results with Phospho-PKMYT1 (Ser83) Antibody, use a 1:1000 dilution as recommended for commercial antibodies like #4281 . Sample preparation should include phosphatase inhibitors to prevent loss of phosphorylation signals. When preparing lysates, rapid processing on ice is essential to preserve phosphorylation status.

The following methodology is recommended:

• Prepare cell/tissue lysates in buffer containing phosphatase inhibitors

• Separate proteins by SDS-PAGE (expect a band around 70 kDa for human PKMYT1)

• Transfer to PVDF or nitrocellulose membrane

• Block with 5% BSA in TBST (not milk, which contains phosphatases)

• Incubate with Phospho-PKMYT1 (Ser83) Antibody at 1:1000 dilution overnight at 4°C

• Wash thoroughly with TBST

• Incubate with appropriate secondary antibody

• Develop using chemiluminescence or fluorescence-based detection

Always include positive controls (such as lysates from cells with activated kinase pathways) and negative controls (such as λ phosphatase-treated lysates) to validate specificity of the phospho-signal .

What is the significance of Ser83 phosphorylation in PKMYT1 function?

Ser83 phosphorylation of PKMYT1 represents a regulatory post-translational modification that affects PKMYT1 activity. While the kinase responsible for phosphorylating human PKMYT1 at Ser83 is not definitively established, research suggests it differs from the mechanism in starfish Myt1, where Akt phosphorylates at the orthologous site . The phosphorylation status of PKMYT1 at Ser83 may be indicative of its activation state and could influence its interaction with substrates like CDK1 and PLK1.

In research contexts, monitoring Ser83 phosphorylation provides insight into the regulatory status of PKMYT1 in different cellular conditions, particularly during cell cycle progression and in response to various signaling pathways. This phosphorylation site may serve as a biomarker for specific cellular states or responses to treatments, especially in cancer research where PKMYT1 has emerged as a potential therapeutic target .

How does PKMYT1 expression vary across cancer types and what are the implications?

PKMYT1 expression shows significant variation across cancer types, with notable overexpression in pancreatic ductal adenocarcinoma (PDAC). In a tissue microarray study of 75 PDAC patient samples, 36% demonstrated high PKMYT1 expression . This overexpression correlates with poor prognosis, suggesting PKMYT1 as both a prognostic marker and potential therapeutic target.

Expression analysis should include:

• IHC staining of patient samples using validated antibodies

• Correlation with clinical outcomes data

• Comparison with normal adjacent tissue

• Evaluation of phosphorylation status using phospho-specific antibodies

The expression pattern of PKMYT1 can inform patient stratification strategies for potential PKMYT1 inhibitor therapies. For instance, patients with high PKMYT1 expression might be more responsive to PKMYT1 inhibitors like RP-6306, particularly in combination with other therapies targeting cell cycle checkpoints .

How can Phospho-PKMYT1 (Ser83) Antibody be used to evaluate PKMYT1 inhibitor efficacy?

Phospho-PKMYT1 (Ser83) Antibody serves as a valuable tool for monitoring PKMYT1 inhibitor efficacy through several methodological approaches:

• Mobility Shift Assay: PKMYT1 inhibition with drugs like RP-6306 induces hyperphosphorylation of PKMYT1, which can be visualized as a mobility shift (decreased electrophoretic mobility) in Western blot analysis. This shift serves as a direct pharmacodynamic marker of PKMYT1 inhibition .

• Substrate Phosphorylation Monitoring: Effective PKMYT1 inhibition reduces CDK1 phosphorylation at Thr14. Measuring the ratio of phospho-CDK1 to total CDK1 provides a quantitative assessment of inhibitor efficacy .

• Time-Course Analysis: Treatment with PKMYT1 inhibitors like RP-6306 should show time-dependent changes in both PKMYT1 mobility and substrate phosphorylation, allowing determination of optimal dosing schedules.

• Combination Therapy Assessment: When evaluating PKMYT1 inhibitors in combination with other agents (e.g., ATR inhibitors), Phospho-PKMYT1 (Ser83) Antibody can help identify synergistic mechanisms by revealing altered phosphorylation patterns .

A typical experimental design would include treatment of cells with varying concentrations of inhibitor, collection of samples at different time points, and Western blot analysis using both phospho-specific and total PKMYT1 antibodies to evaluate changes in phosphorylation status.

What is the relationship between PKMYT1 and PLK1 in cancer progression?

Recent research has uncovered a previously unrecognized relationship between PKMYT1 and PLK1 that extends beyond their canonical roles in cell cycle regulation:

• Expression Correlation: PKMYT1 positively regulates PLK1 protein expression. PKMYT1 knockout or pharmacological inhibition downregulates PLK1 expression in PDAC cell lines, while PKMYT1 overexpression increases PLK1 protein levels .

• Protein Stability Regulation: PKMYT1 influences PLK1 protein stability by regulating its proteasome-mediated degradation. Cycloheximide (CHX) chase experiments demonstrate that PKMYT1 knockout significantly decreases PLK1 half-life, and this effect can be blocked by proteasome inhibitors like MG132 .

• Direct Phosphorylation: In vitro experiments suggest that PKMYT1 can directly phosphorylate PLK1, representing a novel kinase-substrate relationship. This phosphorylation may regulate PLK1 activity or stability .

• Functional Redundancy: PLK1 knockout phenocopies many effects of PKMYT1 ablation, including cell proliferation defects, G2/M arrest, and apoptosis induction. Importantly, enforced PLK1 expression can partially rescue growth defects in PKMYT1-ablated PDAC cells .

This relationship suggests that PKMYT1's oncogenic functions may be partially mediated through PLK1 regulation, providing a mechanistic basis for the development of targeted therapeutic strategies.

How does PKMYT1 inhibition contribute to synthetic lethality in combination therapies?

PKMYT1 inhibition creates synthetic lethality in combination with specific pathway inhibitors through several mechanisms:

• CDK1 Activation and Unscheduled Mitosis: PKMYT1 inhibition prevents CDK1 phosphorylation at Thr14, leading to premature CDK1 activation. When combined with ATR inhibitors in CCNE1-amplified cells, this forces cells into unscheduled mitosis before completion of DNA replication, causing catastrophic DNA damage and cell death .

• Cell Cycle Checkpoint Disruption: The combination of PKMYT1 inhibition with ATR inhibition (e.g., RP-6306 + RP-3500) synergistically disrupts cell cycle checkpoints, particularly in cancers with specific genetic backgrounds like CCNE1 amplification .

• Genetic Context Dependency: The synthetic lethality of PKMYT1 inhibition shows strong genetic context dependency. For example:

  • CCNE1-amplified cells are highly sensitive to PKMYT1i-ATRi combinations

  • TP53 function modulates sensitivity to PKMYT1 inhibition

  • PRKDC activation influences response to PKMYT1 inhibition

• Tumor-Specific Effects: Research shows that PKMYT1i-ATRi combinations display cytotoxicity in CCNE1-overexpressing cells at concentrations that spare normal cells and cells with other genetic alterations (like ATM or BRCA1 mutations) .

This data demonstrates that CCNE1 amplification/overexpression serves as a robust biomarker for sensitivity to PKMYT1i-ATRi combinations, with potential clinical implications for targeted therapy development .

What methodologies are most effective for analyzing PKMYT1 phosphorylation dynamics during cell cycle progression?

Analyzing PKMYT1 phosphorylation dynamics during cell cycle progression requires multi-faceted approaches:

• Synchronization Methods:

  • Double thymidine block for G1/S boundary arrest

  • Nocodazole treatment for M-phase arrest

  • Serum starvation for G0/G1 synchronization

  • Release experiments with timed collection points throughout the cell cycle

• Analytical Techniques:

  • Western blotting with Phospho-PKMYT1 (Ser83) Antibody alongside total PKMYT1 antibody

  • Flow cytometry combining phospho-protein detection with DNA content analysis

  • Immunofluorescence microscopy for subcellular localization of phosphorylated PKMYT1

  • Phospho-proteomics using mass spectrometry for comprehensive phosphorylation site analysis

• Co-analysis with Cell Cycle Markers:

  • Cyclin B1 and phospho-Histone H3 (Ser10) for mitotic cells

  • Cyclin E for G1/S transition

  • CDK1 phosphorylation status (pThr14, pTyr15)

  • PLK1 expression and activation

• Inhibitor Studies:

  • Treatment with phosphatase inhibitors to preserve phosphorylation

  • CDK inhibitors to determine dependency relationships

  • Kinase inhibitors to identify upstream regulators of Ser83 phosphorylation

By combining these approaches, researchers can generate comprehensive temporal profiles of PKMYT1 phosphorylation across the cell cycle and in response to various perturbations, providing insight into its regulatory mechanisms.

What controls are essential when working with Phospho-PKMYT1 (Ser83) Antibody?

Implementing robust controls is critical for reliable phospho-protein detection:

• Positive Controls:

  • Lysates from cells with known activation of pathways affecting PKMYT1 phosphorylation

  • Recombinant phosphorylated PKMYT1 protein (if available)

  • Cells treated with phosphatase inhibitors to maximize phosphorylation signals

• Negative Controls:

  • λ phosphatase-treated samples to remove phosphorylation

  • PKMYT1 knockout or knockdown cells to confirm antibody specificity

  • Blocking peptide competition assays to validate signal specificity

• Experimental Controls:

  • Total PKMYT1 antibody detection in parallel to normalize phospho-signal

  • Loading controls (β-actin, GAPDH, or total protein staining)

  • Untreated/vehicle-treated samples as baseline

• Method Validation Controls:

  • Antibody titration to determine optimal concentration

  • Secondary antibody-only controls to assess background

  • Multiple biological replicates to ensure reproducibility

For phosphatase treatment validation, a simple experimental design involves:

• Split your sample into two aliquots

• Treat one with λ phosphatase

• Process both samples identically

• Compare Western blot signals using Phospho-PKMYT1 (Ser83) Antibody

The phosphatase-treated sample should show significantly reduced or absent signal compared to the untreated sample if the antibody is truly phospho-specific .

How can sample preparation be optimized to preserve PKMYT1 phosphorylation status?

Preserving phosphorylation status requires careful sample handling and preparation:

• Lysis Buffer Composition:

  • Include multiple phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate)

  • Add protease inhibitor cocktail to prevent protein degradation

  • Use detergents appropriate for membrane proteins (PKMYT1 is membrane-associated)

  • Maintain buffer at pH 7.4-7.6 to preserve phosphorylation

• Harvesting Protocol:

  • Process samples rapidly to minimize dephosphorylation

  • Maintain samples at 4°C throughout processing

  • For adherent cells, consider direct lysis in plate after rapid PBS washing

  • For tissue samples, snap-freeze immediately after collection

• Storage Considerations:

  • Aliquot lysates to avoid freeze-thaw cycles

  • Store at -80°C for long-term preservation

  • Add glycerol (10%) to prevent damage from freezing

• Sample Processing:

  • Avoid excessive heat during processing (keep samples on ice)

  • When possible, use methods that denature proteins quickly

  • For Western blotting, load samples promptly after preparation

  • Consider phospho-protein enrichment techniques for low abundance targets

• Special Considerations for IHC/IF:

  • Use phospho-optimized fixatives (avoid long formalin fixation)

  • Process tissue rapidly after collection

  • Consider phospho-epitope retrieval methods

By implementing these approaches, researchers can maximize the preservation of phosphorylation status and improve the reliability of experiments using Phospho-PKMYT1 (Ser83) Antibody.

What are common issues when detecting Phospho-PKMYT1 (Ser83) and how can they be resolved?

Several challenges may arise when working with Phospho-PKMYT1 (Ser83) Antibody:

• Weak or Absent Signal:

  • Cause: Insufficient protein, dephosphorylation during processing, or suboptimal antibody concentration

  • Solution: Increase protein loading, enhance phosphatase inhibition, optimize antibody dilution, and extend exposure time

• Multiple Bands or Non-specific Signals:

  • Cause: Cross-reactivity with related proteins, degradation products, or insufficient blocking

  • Solution: Increase blocking stringency, validate with PKMYT1 knockout controls, and use monoclonal antibodies if available

• Inconsistent Results Between Experiments:

  • Cause: Variations in cell culture conditions, phosphorylation status, or sample handling

  • Solution: Standardize culture conditions, synchronize cells when appropriate, and implement consistent sample processing protocols

• Mobility Shift Complications:

  • Cause: PKMYT1 inhibitors can cause hyperphosphorylation and mobility shifts that affect band detection

  • Solution: Include both phospho-specific and total PKMYT1 antibodies, and use gradient gels for better resolution of shifted bands

• Signal Interference in Cancer Samples:

  • Cause: Variable PKMYT1 expression levels across samples or altered phosphorylation patterns in cancer

  • Solution: Include appropriate positive controls matched to tumor type, normalize to total PKMYT1, and consider using multiple antibodies targeting different phospho-sites

• Sample-Specific Issues:

  • Cause: Sample-specific constituents that interfere with antibody binding or detection

  • Solution: Modify extraction protocols, try alternative detergents, or implement sample clean-up procedures

A troubleshooting matrix with common problems, causes, and solutions can be developed for laboratory reference to systematically address detection challenges.

How should experiments be designed to investigate PKMYT1's dual role in CDK1 regulation and PLK1 interaction?

Investigating PKMYT1's dual role requires carefully designed experiments addressing both functions:

• Sequential Immunoprecipitation Approach:

  • Immunoprecipitate PKMYT1 from cell lysates

  • Analyze co-precipitated proteins (CDK1, PLK1) by Western blot

  • Perform reverse IP with CDK1 or PLK1 antibodies to confirm interactions

  • Include phospho-specific antibodies to assess phosphorylation status of interacting proteins

• Mutational Analysis:

  • Generate phospho-mimetic (S83D) and phospho-deficient (S83A) PKMYT1 mutants

  • Express in PKMYT1-knockout cells to avoid endogenous protein interference

  • Assess effects on:

    • CDK1 phosphorylation at Thr14 and Tyr15

    • PLK1 expression, stability, and phosphorylation

    • Cell cycle progression and mitotic entry timing

• Time-Resolved Analysis of Protein Complexes:

  • Synchronize cells at different cell cycle phases

  • Analyze PKMYT1-CDK1-PLK1 interactions by co-IP at each phase

  • Monitor phosphorylation status changes during cell cycle progression

  • Correlate with functional outcomes (e.g., mitotic entry, cell proliferation)

• In Vitro Kinase Assays:

  • Purify recombinant PKMYT1 (WT and mutants)

  • Perform kinase assays with purified CDK1 and PLK1 as substrates

  • Analyze phosphorylation by autoradiography or phospho-specific antibodies

  • Include ATP competition assays to assess kinase preferences

• Inhibitor Studies with Temporal Resolution:

  • Treat cells with PKMYT1 inhibitors (e.g., RP-6306)

  • Collect samples at multiple time points

  • Analyze effects on both CDK1 and PLK1 pathways

  • Determine temporal relationships between pathway alterations

These experimental approaches can help delineate the relative contributions of PKMYT1's dual functions to cell cycle regulation and cancer progression, informing more targeted therapeutic strategies .

How can PKMYT1 phosphorylation status be used as a biomarker in cancer patient samples?

PKMYT1 phosphorylation status has potential as a cancer biomarker that can be assessed through multiple methodological approaches:

• IHC Protocol Development:

  • Optimize antigen retrieval methods specifically for phospho-epitopes

  • Validate antibody specificity with phosphatase-treated controls

  • Develop standardized scoring systems (H-score or Allred)

  • Correlate with patient outcomes in retrospective cohorts

• Biomarker Validation Strategy:

  • Analyze phospho-PKMYT1 (Ser83) levels in tumor versus matched normal tissue

  • Correlate expression with clinicopathological features

  • Assess relationship with patient survival (Kaplan-Meier analysis)

  • Evaluate as a predictive marker for response to cell cycle-targeted therapies

• Multi-marker Panels:

  • Combine phospho-PKMYT1 with other cell cycle regulators (CDK1, PLK1, cyclins)

  • Develop multiplexed IHC or immunofluorescence protocols

  • Create algorithm-based scoring for complex biomarker patterns

  • Validate in independent cohorts

• Liquid Biopsy Applications:

  • Explore detection of phospho-PKMYT1 in circulating tumor cells

  • Investigate correlation with disease progression

  • Monitor treatment response through serial sampling

  • Develop minimally invasive prognostic/predictive assays

High expression of PKMYT1 has been associated with poor prognosis in pancreatic ductal adenocarcinoma patients, with 36% of cases showing elevated expression in a 75-patient cohort . This suggests phosphorylation status could provide additional prognostic or predictive information beyond total protein levels.

What methodological approaches are most effective for evaluating PKMYT1 inhibitor efficacy in preclinical models?

Evaluating PKMYT1 inhibitor efficacy requires comprehensive preclinical assessment:

• In Vitro Models and Assays:

  • Cell viability assays across concentration ranges (IC50 determination)

  • Colony formation assays for long-term growth inhibition assessment

  • Cell cycle analysis by flow cytometry (quantify G2/M arrest, mitotic catastrophe)

  • Combination studies with synergy calculation methods (e.g., CDI < 0.7 indicating significant synergy)

• Mechanistic Biomarkers:

  • Western blot analysis of CDK1 phosphorylation status

  • PKMYT1 mobility shift assay (indicative of hyperphosphorylation)

  • PLK1 expression and phosphorylation monitoring

  • DNA damage markers (γH2AX) to assess consequences of checkpoint abrogation

• Advanced Model Systems:

  • Patient-derived organoids for personalized drug response testing

  • 3D spheroid cultures to better reflect tumor microenvironment

  • Co-culture systems to assess effects on tumor-stroma interactions

  • Ex vivo tissue slice cultures to maintain tissue architecture

• In Vivo Efficacy Assessment:

  • Cell line-derived xenograft models

  • Patient-derived xenograft models (more clinically relevant)

  • Genetic context-specific models (e.g., CCNE1-amplified models)

  • Pharmacodynamic biomarker analysis in tumor samples

How does the genetic context influence response to PKMYT1-targeted therapies?

Genetic context profoundly influences PKMYT1 inhibitor efficacy, requiring strategic patient selection:

• CCNE1 Amplification/Overexpression:

  • Strong predictor of sensitivity to PKMYT1 inhibition, particularly in combination with ATR inhibitors

  • Linear relationship observed between CCNE1 copy number and synergistic effect (CDI) of PKMYT1i-ATRi combination

  • Lower effective concentrations needed in CCNE1-amplified versus non-amplified backgrounds

• TP53 Status:

  • Loss of TP53 function modulates sensitivity to PKMYT1 inhibition

  • May enhance dependency on PKMYT1 for cell cycle regulation

  • Potential synthetic lethal interaction to exploit therapeutically

• PRKDC Activation:

  • PRKDC (DNA-PK catalytic subunit) activation status influences response to PKMYT1 inhibition

  • May affect DNA damage response and repair mechanisms

  • Could serve as a biomarker for patient stratification

• HR Deficiency Context:

  • BRCA1/2 or ATM mutations do not appear to sensitize cells to low-dose PKMYT1i-ATRi combinations to the same extent as CCNE1 amplification

  • Different therapeutic strategies may be more appropriate for these genetic backgrounds

Experimental data comparing isogenic cell lines shows that at the same concentration (24.7 nM PKMYT1i + 12.3 nM ATRi), only CCNE1-overexpressing cells experienced cytotoxicity, while parental, ATM-/-, and BRCA1-/- counterparts were spared . This highlights the potential for highly selective targeting based on genetic context.

What are the methodological considerations for developing Phospho-PKMYT1 (Ser83) detection in clinical specimens?

Developing clinical-grade phospho-protein detection methods requires addressing several technical challenges:

• Pre-analytical Variables:

  • Standardize tissue collection protocols to minimize ischemia time

  • Optimize fixation methods to preserve phospho-epitopes (cold formalin, shorter fixation)

  • Develop tissue processing SOPs specifically for phospho-proteins

  • Implement rapid preservation methods (e.g., PAXgene tissue system)

• Analytical Validation:

  • Determine antibody specificity through multiple orthogonal methods

  • Establish precision metrics (intra-assay and inter-assay variability)

  • Determine limits of detection and quantification

  • Create calibration standards for semi-quantitative assessment

• Scoring System Development:

  • Create training sets with known positive and negative controls

  • Develop digital image analysis algorithms for standardized quantification

  • Establish thresholds for positive/negative or graded scoring

  • Assess inter-observer and intra-observer variability

• Tissue Heterogeneity Considerations:

  • Implement tissue microarray technology for high-throughput screening

  • Address intratumoral heterogeneity through multiple sampling

  • Develop multiplex methods to assess phospho-PKMYT1 in specific cell populations

  • Use laser capture microdissection for pure tumor cell population analysis

• Quality Control Program:

  • Include run controls (positive, negative, phosphatase-treated)

  • Participate in proficiency testing programs

  • Implement regular antibody lot validation

  • Monitor long-term assay performance metrics

These methodological considerations are essential for translating research findings into clinical applications, particularly for companion diagnostic development for PKMYT1-targeted therapies in CCNE1-amplified or PDAC patient populations .